By SquaredTown on January 8, 2026
Phase 2 data demonstrated 17.5-month median overall survival in advanced, chemo-refractory patients with microsatellite stable colorectal cancer (MSS-CRC) Company closed $22M financing to support randomized Phase 2b trial; IND cleared and study initiated; Interim results anticipated in...